ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Dendritic Cell Vaccine May Boost Median Survival

March 25, 2011

FDA cancer therapeutics review split among three units in reorganization.

October 10, 2003

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

Clinical Center’s Cancer Nursing Recruitment Improved

January 10, 1986

Horvitz Wins BMS Award In Neuroscience; Group Room To Discuss Congressional Issues.

February 22, 2002

Centers Network Release “Version 1.0” Of Clinical Guidelines for Eight Cancers

March 15, 1996